Trial Profile
A PHASE 1 RANDOMIZED, ACTIVE-CONTROLLED, DOUBLEBLIND, SINGLE CENTRE STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF AN ADJUVANTED SARS-CoV-2 UQSC2 PROTEIN SUBUNIT VACCINE IN HEALTHY ADULTS, AGED 18 TO 50 YEARS.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Mar 2024
Price :
$35
*
At a glance
- Drugs NVX CoV 2373 (Primary) ; Matrix M
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man; Pharmacodynamics; Therapeutic Use
- 16 Jun 2023 Status changed from not yet recruiting to completed.
- 12 Apr 2023 Planned initiation date changed from 10 Mar 2023 to 20 Apr 2023.
- 23 Mar 2023 New trial record